Skip to main content
editorial
. 2016 Apr 29;10(5):702–726. doi: 10.1007/s12072-016-9717-6

Fig. 1.

Fig. 1

Sustained virological response (SVR) rates (%) of daily ledipasvir (LDV) and sofosbuvir (SOF). a Treatment-naïve patients with HCV genotype 1, b Treatment-experienced patients with HCV genotype 1